Advertisement|Remove ads.

Insmed Incorporated (INSM) said on Tuesday that its mid-stage study evaluating brensocatib in adult patients with moderate to severe hidradenitis suppurativa failed to meet its goals.
The trial did not meet the trials’s primary or secondary endpoints in either the 10 mg or 40 mg treatment arms though the drug was well tolerated.
The company said that it will subsequently discontinue development of brensocatib in hidradenitis suppurativa, a chronic, non-contagious inflammatory skin condition characterized by painful, recurring lumps and abscesses.
Get updates to this developing story directly on Stocktwits.